Unlimited Access

Unlimited access to the most powerful analytical tools in finance.

20M+ Securities
Real-time Data
AI Insights
50Y History
8K+ News
Subscribe for $2
Overview
Profile
Eagle Pharmaceuticals Stock

Eagle Pharmaceuticals Stock EGRX

EGRX
US2697961082
A1XEDS

Price

3.00
Today +/-
+0.09
Today %
+3.56 %

Eagle Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Eagle Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Eagle Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Eagle Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Eagle Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Eagle Pharmaceuticals Stock Price History

DateEagle Pharmaceuticals Price
7/3/20253.00 undefined
7/2/20252.90 undefined
7/1/20252.36 undefined
6/27/20252.90 undefined
6/25/20252.70 undefined
6/24/20252.75 undefined
6/23/20252.79 undefined
6/19/20252.88 undefined
6/16/20252.35 undefined
6/13/20252.40 undefined
6/12/20252.35 undefined
6/10/20252.30 undefined
6/10/20252.10 undefined

Eagle Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Eagle Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Eagle Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Eagle Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Eagle Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Eagle Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Eagle Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Eagle Pharmaceuticals’s growth potential.

Eagle Pharmaceuticals Revenue, EBIT and net profit per share

DateEagle Pharmaceuticals RevenueEagle Pharmaceuticals EBITEagle Pharmaceuticals Net Income
2027e330.48 M undefined80.07 M undefined55.72 M undefined
2026e320.69 M undefined79.36 M undefined55.99 M undefined
2025e228.48 M undefined50.8 M undefined39.95 M undefined
2024e215.73 M undefined11.63 M undefined43.69 M undefined
2023e263.51 M undefined35.6 M undefined61.2 M undefined
2022316.6 M undefined102.4 M undefined35.6 M undefined
2021171.5 M undefined2.8 M undefined-8.6 M undefined
2020187.8 M undefined33 M undefined12 M undefined
2019195.9 M undefined21.8 M undefined14.3 M undefined
2018213.3 M undefined47.2 M undefined31.9 M undefined
2017236.7 M undefined82.9 M undefined51.9 M undefined
2016189.5 M undefined51.6 M undefined81.5 M undefined
201566.2 M undefined2.6 M undefined2.6 M undefined
201419.1 M undefined-18.8 M undefined-19.6 M undefined
201313.7 M undefined-8.5 M undefined-9.9 M undefined
20122.5 M undefined-19.8 M undefined-23.3 M undefined
20119.5 M undefined-5.5 M undefined-8.7 M undefined

Eagle Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
2011201220132014201520162017201820192020202120222023e2024e2025e2026e2027e
92131966189236213195187171316263215228320330
--77.78550.0046.15247.37186.3624.87-9.75-8.45-4.10-8.5684.80-16.77-18.256.0540.353.13
77.7811,050.0046.1536.8475.7670.9075.8570.8969.2375.9475.4469.9484.03102.7996.9369.0666.97
70675013417915113514212922100000
-8-23-9-1928151311412-8356143395555
-187.50-60.87111.11-110.533,950.00-37.04-39.22-54.84-14.29-166.67-537.5074.29-29.51-9.3041.03-
13.913.913.91016.316.415.915.314.113.813.113.100000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Eagle Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Eagle Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (k)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
201120122013201420152016201720182019202020212022
                       
12.66.610.542.779.152.8114.778.8109.8103.297.755.3
0.31.65.17.326.342.253.866.54851.141.172.4
000000000001,000
1.10.101.3152.75.18.36.68.121.947.8
0.80.61.91.71.911.415.110.315.13.711.912.2
14.88.917.553122.3109.1188.7163.9179.5166.1172.6188.7
0.70.50.40.32.23.36.82.45.92.11.61.2
000000000000
000000000000
0000033.423.318.115.612.910.7118.3
0000039.739.739.739.739.739.745
0.10.10.200.128.811.514.513.932.429.152.9
0.80.60.60.32.3105.281.374.775.187.181.1217.4
15.69.518.153.3124.6214.3270238.6254.6253.2253.7406.1
                       
77.481.390000000000
12.114.2137.3197.4213.9233.6256.5278.5305.4325.8366.3
-72.2-95.5-102.1-104.2-107.1-25.726.358.272.584.575.9111.5
0000000000-0.1-1.1
000000000000
6.2-12.12.133.190.3188.2259.9314.7351389.9401.6476.7
1.51.41.24.13.915.7279.95.56.316.419
1.81.33.19.723.923.515.423.528.423.832.361.6
69.5106.66.51.70000024.2
08.60000000000
0000004.96.35825.66.3
9.320.814.320.434.340.947.339.738.938.174.3111.1
00000042.938.233.625.1056.2
000000000000
00.71.70022.10.70342.95.3
00.71.70022.143.638.236.629.12.961.5
9.321.51620.434.36390.977.975.567.277.2172.6
15.59.418.153.5124.6251.2350.8392.6426.5457.1478.8649.3
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Eagle Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Eagle Pharmaceuticals's financial health and stability.

Assets

Eagle Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Eagle Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Eagle Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Eagle Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
201120122013201420152016201720182019202020212022
-5-19-6-1728151311411-835
0000013343312
00000-3017-20-1-3-8
-52-22-16-8-29-71409-16
0131818304644594644
000000022211
000002102661028
-9-15-5-13-953585255492850
0000-1-15-500000
-421-20-1-45-500-18-5-86
-431-200-29000-17-5-86
000000000000
179000048-3-6-5-812
0094655-33-39-64-17-31-18-16
17994655-338-88-24-37-28-6
-------1.00-19.00--1.00-1.00-2.00
000000000000
3-351244-2661-3530-6-5-42
-9.86-15.58-5.92-13.89-11.637.3753.7352.2555.2148.7527.950.52
000000000000

Eagle Pharmaceuticals stock margins

The Eagle Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Eagle Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Eagle Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Eagle Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Eagle Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Eagle Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Eagle Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Eagle Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Eagle Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Eagle Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Eagle Pharmaceuticals Margin History

Eagle Pharmaceuticals Gross marginEagle Pharmaceuticals Profit marginEagle Pharmaceuticals EBIT marginEagle Pharmaceuticals Profit margin
2027e70.03 %24.23 %16.86 %
2026e70.03 %24.75 %17.46 %
2025e70.03 %22.23 %17.49 %
2024e70.03 %5.39 %20.25 %
2023e70.03 %13.51 %23.22 %
202270.03 %32.34 %11.24 %
202175.45 %1.63 %-5.01 %
202075.77 %17.57 %6.39 %
201968.91 %11.13 %7.3 %
201870.98 %22.13 %14.96 %
201775.83 %35.02 %21.93 %
201670.82 %27.23 %43.01 %
201576.44 %3.93 %3.93 %
201438.74 %-98.43 %-102.62 %
201345.99 %-62.04 %-72.26 %
2012-24 %-792 %-932 %
201181.05 %-57.89 %-91.58 %

Eagle Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Eagle Pharmaceuticals earnings per share therefore indicates how much revenue Eagle Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Eagle Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Eagle Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Eagle Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Eagle Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eagle Pharmaceuticals Revenue, EBIT and net profit per share

DateEagle Pharmaceuticals Sales per ShareEagle Pharmaceuticals EBIT per shareEagle Pharmaceuticals Earnings per Share
2027e25.23 undefined0 undefined4.25 undefined
2026e24.48 undefined0 undefined4.27 undefined
2025e17.44 undefined0 undefined3.05 undefined
2024e16.47 undefined0 undefined3.34 undefined
2023e20.12 undefined0 undefined4.67 undefined
202224.17 undefined7.82 undefined2.72 undefined
202113.09 undefined0.21 undefined-0.66 undefined
202013.61 undefined2.39 undefined0.87 undefined
201913.89 undefined1.55 undefined1.01 undefined
201813.94 undefined3.08 undefined2.08 undefined
201714.89 undefined5.21 undefined3.26 undefined
201611.55 undefined3.15 undefined4.97 undefined
20154.06 undefined0.16 undefined0.16 undefined
20141.91 undefined-1.88 undefined-1.96 undefined
20130.99 undefined-0.61 undefined-0.71 undefined
20120.18 undefined-1.42 undefined-1.68 undefined
20110.68 undefined-0.4 undefined-0.63 undefined

Eagle Pharmaceuticals business model

Eagle Pharmaceuticals Inc was founded in 2007 and is based in New Jersey, USA. The company operates in the field of development and marketing of pharmaceutical products. History Eagle Pharmaceuticals was founded by Scott Tarriff, an experienced entrepreneur and expert in the fields of pharmacy and biotechnology. The goal was to create a company focused on developing generic drugs with improved effectiveness. Eagle Pharmaceuticals started with two products - Argatroban and Ryanodex. Argatroban is an anticoagulant used in the treatment of thrombosis. Ryanodex is a muscle relaxant for patients suffering from malignant hyperthermia. Business model Eagle Pharmaceuticals has a unique business model that sets it apart from other pharmaceutical companies. They focus on developing generic drugs with improved effectiveness instead of entirely new drugs. The company also focuses on licensing technologies rather than spending money on research and development. The company works closely with doctors and hospitals to ensure that their products meet the needs of patients. Divisions Eagle Pharmaceuticals is divided into two business segments - branded and generic products. Branded products: The company develops and distributes generic products with improved effectiveness. These include products such as Ryanodex, Bendeka, Belrapzo, and Pemetrexed. Generic products: The company has a wide range of generic products used in the areas of anticoagulants, oncology, and pain management. These include products such as Argatroban, Docetaxel, Phenylephrine HCl, and Bivalirudin. Products Argatroban: An anticoagulant used in patients with thrombosis or thromboembolic events. Ryanodex: A muscle relaxant used in patients suffering from malignant hyperthermia. Bendeka: A medication for leukemia used in combination with other chemotherapies. Belrapzo: A medication for certain types of cancer used in combination with other chemotherapies. Pemetrexed: A medication for various cancer diseases, such as lung and breast cancer. Docetaxel: A medication for various cancer diseases, such as breast cancer, lung cancer, and prostate cancer. Phenylephrine HCl: A medication for high blood pressure and bronchodilation. Bivalirudin: An anticoagulant used in patients undergoing angioplasty or coronary bypass surgery. In summary, Eagle Pharmaceuticals is an innovative pharmaceutical company that focuses on developing drugs with improved effectiveness. The company has a wide range of products in the areas of oncology, pain management, and anticoagulants. It works closely with doctors and hospitals to ensure that its products meet the needs of patients. Eagle Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Eagle Pharmaceuticals SWOT Analysis

Strengths

Eagle Pharmaceuticals Inc possesses several strengths that contribute to its success in the market:

Eagle Pharmaceuticals Inc has established a robust market position in the pharmaceutical industry. This position enables the company to leverage its brand reputation and attract a loyal customer base.

The company's product portfolio is characterized by its innovative and differentiated offerings. Eagle Pharmaceuticals Inc invests in research and development to continuously develop new drugs and drug delivery systems with superior therapeutic benefits.

Eagle Pharmaceuticals Inc has formed strategic partnerships with key stakeholders in the healthcare sector. These collaborations allow the company to expand its reach, gain access to new markets, and capitalize on mutual strengths.

Weaknesses

Despite its strengths, Eagle Pharmaceuticals Inc also faces some weaknesses that could hinder its growth:

The company heavily relies on a few key products for its revenue generation. This lack of diversification makes Eagle Pharmaceuticals Inc vulnerable to changes in market demand or regulatory restrictions on specific drugs.

Eagle Pharmaceuticals Inc relies on external contract manufacturers for the production of its drugs. This reliance introduces a level of dependency on third-party suppliers, potentially exposing the company to supply chain disruptions or quality control issues.

The company's operations are primarily focused on the domestic market, limiting its exposure to international markets. This narrow geographic footprint means Eagle Pharmaceuticals Inc may miss out on significant growth opportunities in global healthcare markets.

Opportunities

There are several potential opportunities that Eagle Pharmaceuticals Inc can explore to drive future growth:

Entering emerging markets presents an opportunity for Eagle Pharmaceuticals Inc to capture untapped customer segments and increase its revenue. These markets often have growing healthcare needs and less competition.

Investing in research and development to develop new drug formulations can provide Eagle Pharmaceuticals Inc with a competitive edge. Introduction of innovative products can attract more customers and generate additional revenue streams.

Seeking strategic acquisitions or partnerships can help Eagle Pharmaceuticals Inc expand its product portfolio, gain market share, and access new technologies. Collaborating with established players in different therapeutic areas can enhance the company's overall offerings.

Threats

Eagle Pharmaceuticals Inc should be mindful of potential threats that could impact its business:

The pharmaceutical industry is highly competitive, with numerous players vying for market share. Intense competition can erode pricing power, increase marketing costs, and potentially impact profitability for Eagle Pharmaceuticals Inc.

Stringent regulations and an evolving regulatory landscape can pose challenges for Eagle Pharmaceuticals Inc. Compliance with various regulatory requirements, including drug approvals, safety standards, and patent protection, is crucial to the company's operations.

Price erosion in the pharmaceutical industry, driven by factors such as generic competition and cost containment efforts by payers, can negatively impact the profitability of Eagle Pharmaceuticals Inc. Additionally, reimbursement pressures from healthcare payers may restrict access to certain drugs or limit pricing flexibility.

Eagle Pharmaceuticals Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Eagle Pharmaceuticals Revenue by Segment

Segmente20222021202020192018
Product sales, net214.54 M USD65.02 M USD72.32 M USD--
Royalty revenue98.27 M USD106.52 M USD110.48 M USD--
License and other revenue3.81 M USD-5 M USD--

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Eagle Pharmaceuticals Revenue by Segment

Segmente20222021202020192018
Royalty revenue---112.9 M USD-
Product sales---73.99 M USD-
Vasopressin63.16 M USD----
Bendeka--15.44 M USD--
License---9 M USD-

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Eagle Pharmaceuticals Revenue by Segment

Segmente20222021202020192018
Belrapzo33.67 M USD23.73 M USD-29.67 M USD-
Ryanodex30.16 M USD25.27 M USD-13.04 M USD-
PEMFEXY67.48 M USD----
Bendeka12.99 M USD----
Other7.08 M USD4.86 M USD-103,000 USD-

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Eagle Pharmaceuticals Revenue by Segment

Segmente20222021202020192018
Royalty revenue----142.93 M USD
Product sales----70.39 M USD
Bendeka-11.17 M USD-31.18 M USD-
Ryanodex--28.27 M USD--
Belrapzo--27.53 M USD--
Other--1.09 M USD--
License and other revenue-----
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Eagle Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Eagle Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Eagle Pharmaceuticals shares outstanding

The number of shares was Eagle Pharmaceuticals in 2024 — This indicates how many shares 13.1 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Eagle Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Eagle Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Eagle Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Eagle Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Eagle Pharmaceuticals.

Eagle Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20231.07 1.18  (10.18 %)2023 Q2
3/31/20231.07 1.26  (17.65 %)2023 Q1
12/31/20220.85 1.1  (29.93 %)2022 Q4
9/30/20220.92 1.12  (21.11 %)2022 Q3
6/30/20223.43 1.56  (-54.53 %)2022 Q2
3/31/20223.96 4.04  (1.99 %)2022 Q1
12/31/20210.96 0.85  (-11.35 %)2021 Q4
9/30/20210.85 0.56  (-34.12 %)2021 Q3
6/30/20210.82 0.93  (13.97 %)2021 Q2
3/31/20210.66 0.24  (-63.8 %)2021 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the Eagle Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

18/ 100

🌱 Environment

3

👫 Social

22

🏛️ Governance

30

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Eagle Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
37.74969 % Nantahala Capital Management, LLC4,945,2094,945,2092/16/2025
11.09256 % Tarriff (Scott L)1,453,1257,6772/28/2024
0.43082 % Ajovista LLC56,43845,2069/30/2024
0.36609 % Cahill (Brian Joseph)47,9581,2772/27/2024
0.18011 % XTX Markets LLC23,5941,15712/31/2024
0.13864 % Simplex Trading, LLC18,1629,80712/31/2024
0.10865 % Barclays Bank PLC14,233-81012/31/2024
0.09160 % Stanley-Laman Group, Ltd.12,000012/31/2024
0.08931 % Norges Bank Investment Management (NBIM)11,70006/30/2023
0.07908 % Graves Michael Joseph10,36002/12/2024
1
2
3
4
5
...
10

Eagle Pharmaceuticals Executives and Management Board

Mr. Michael Graves

(60)
Eagle Pharmaceuticals Interim Executive Chairman of the Board, Interim Principal Executive Officer (since 2013)
Compensation 391,026

Mr. Steven Ratoff

(81)
Eagle Pharmaceuticals Director (since 2007)
Compensation 331,026

Mr. Robert Glenning

(62)
Eagle Pharmaceuticals Independent Director
Compensation 324,776

Mr. Richard Edlin

(62)
Eagle Pharmaceuticals Independent Director
Compensation 312,276

Dr. Luciana Borio

(53)
Eagle Pharmaceuticals Independent Director
Compensation 308,526
1
2

Most common questions regarding Eagle Pharmaceuticals

What values and corporate philosophy does Eagle Pharmaceuticals represent?

Eagle Pharmaceuticals Inc is an established pharmaceutical company that upholds core values of innovation, integrity, and patient-centered approach. Committed to providing high-quality solutions, Eagle Pharmaceuticals Inc aims to improve patient outcomes by developing and commercializing injectable products. The company focuses on enhancing existing drugs through patent-protected modifications, promoting efficacy and safety. Eagle Pharmaceuticals Inc is dedicated to developing products that address unmet medical needs and offer value to both healthcare professionals and patients. With a strong emphasis on research and development, Eagle Pharmaceuticals Inc strives to make a positive impact on the pharmaceutical industry and improve the lives of individuals through its innovative offerings.

In which countries and regions is Eagle Pharmaceuticals primarily present?

Eagle Pharmaceuticals Inc primarily operates in the United States and focuses on the development and commercialization of injectable products. The company's presence is primarily centered in North America.

What significant milestones has the company Eagle Pharmaceuticals achieved?

Eagle Pharmaceuticals Inc has achieved significant milestones, positioning itself as a key player in the pharmaceutical industry. The company successfully developed innovative and improved formulations of existing drugs, such as Ryanodex® and BENDEKA®. These formulations received FDA approvals, demonstrating the company's commitment to delivering better treatment options for patients. Eagle Pharmaceuticals Inc also achieved multiple partnerships and collaborations, expanding its portfolio and global reach. The company's dedication to research and development has paved the way for future advancements in healthcare. As a result, Eagle Pharmaceuticals Inc continues to enhance its presence in the market, offering innovative solutions that address critical medical needs.

What is the history and background of the company Eagle Pharmaceuticals?

Eagle Pharmaceuticals Inc, a renowned pharmaceutical company, has a rich history and background. Established in 2007, the company is headquartered in Woodcliff Lake, New Jersey. Eagle Pharmaceuticals focuses on developing and commercializing innovative injectable drugs. With a strong emphasis on novel formulations and techniques, they aim to enhance patient care and expand treatment options. The company's dedication to research and development has resulted in multiple FDA-approved medications, addressing critical medical needs. Eagle Pharmaceuticals Inc continues to thrive in the pharmaceutical industry, leveraging its expertise and commitment to delivering high-quality therapies for patients worldwide.

Who are the main competitors of Eagle Pharmaceuticals in the market?

The main competitors of Eagle Pharmaceuticals Inc in the market are Sandoz Inc, Fresenius Kabi USA LLC, and Akorn Inc.

In which industries is Eagle Pharmaceuticals primarily active?

Eagle Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Eagle Pharmaceuticals?

The business model of Eagle Pharmaceuticals Inc revolves around the development and commercialization of injectable products in the healthcare sector. Eagle Pharmaceuticals focuses on creating novel formulations of existing FDA-approved drugs, thereby improving therapeutic options and patient outcomes. Through strategic partnerships and collaborations, the company aims to enhance its product portfolio and expand its market reach. By leveraging its expertise and innovative technologies, Eagle Pharmaceuticals Inc strives to provide safe, effective, and cost-efficient solutions for various medical conditions. The company's commitment to research and development, alongside its strong industry presence, positions it as a trusted player in the pharmaceutical market.

What is the P/E ratio of Eagle Pharmaceuticals 2025?

The Eagle Pharmaceuticals P/E ratio is 0.98.

What is the P/S ratio of Eagle Pharmaceuticals 2025?

The Eagle Pharmaceuticals P/S ratio is 0.17.

What is the Quality Investing of Eagle Pharmaceuticals?

The Quality Investing for Eagle Pharmaceuticals is 7/10.

What is the revenue of Eagle Pharmaceuticals 2025?

The expected Eagle Pharmaceuticals revenue is 228.48 M USD.

How high is the profit of Eagle Pharmaceuticals 2025?

The expected Eagle Pharmaceuticals profit is 39.95 M USD.

What is the business model of Eagle Pharmaceuticals

The business model of Eagle Pharmaceuticals is focused on developing and commercializing specialized pharmaceutical products and therapies for the treatment of serious diseases. The company offers a wide range of products for various medical conditions, including treatments for bleeding and malignant hyperthermia. They also engage in licensing agreements with other companies to generate revenue from their intellectual property. Eagle Pharmaceuticals utilizes a differentiated marketing strategy, collaborates closely with healthcare professionals, and invests heavily in research and development to achieve a strong presence in the market.

What is the Eagle Pharmaceuticals dividend?

Eagle Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Eagle Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Eagle Pharmaceuticals or the company does not pay out a dividend.

What is the Eagle Pharmaceuticals ISIN?

The ISIN of Eagle Pharmaceuticals is US2697961082.

What is the Eagle Pharmaceuticals WKN?

The WKN of Eagle Pharmaceuticals is A1XEDS.

What is the Eagle Pharmaceuticals ticker?

The ticker of Eagle Pharmaceuticals is EGRX.

How much dividend does Eagle Pharmaceuticals pay?

Over the past 12 months, Eagle Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eagle Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Eagle Pharmaceuticals?

The current dividend yield of Eagle Pharmaceuticals is .

When does Eagle Pharmaceuticals pay dividends?

Eagle Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Eagle Pharmaceuticals?

Eagle Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Eagle Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Eagle Pharmaceuticals located?

Eagle Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eagle Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eagle Pharmaceuticals from 7/7/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/7/2025.

When did Eagle Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/7/2025.

What was the dividend of Eagle Pharmaceuticals in the year 2024?

In the year 2024, Eagle Pharmaceuticals distributed 0 USD as dividends.

In which currency does Eagle Pharmaceuticals pay out the dividend?

The dividends of Eagle Pharmaceuticals are distributed in USD.

All fundamentals about Eagle Pharmaceuticals

Our stock analysis for Eagle Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eagle Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.